Dr. Reddy's Laboratories Limited has informed the Exchange regarding Board meeting held on May 09, 2025.
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's reported Q4FY25 consolidated revenue of Rs. 85,060 Mn, up 20% YoY (12% underlying, excluding the newly acquired NRT business), and FY25 revenue of Rs. 325,535 Mn, up 17% YoY. Profit after tax (attributable to equity holders) rose 22% YoY to Rs. 15,939 Mn in Q4 but only 2% YoY to Rs. 56,544 Mn for the full year. EBITDA margin expanded to 29.1% in Q4 from 26.4% a year earlier. The Board recommended a final dividend of Rs. 8 per share (record date July 10, 2025) and re-appointed G V Prasad as Co-Chairman & MD for another 5 years from January 30, 2026. The company received an unmodified audit opinion, and the new NRT (Haleon) and Nestle nutraceuticals businesses contributed meaningfully to the year's growth.
Strong Q4 print and the dividend signal are positive for shareholders, but the modest 2% full-year PAT growth and the ongoing US FCPA investigation are watchpoints. Leadership continuity and a clean audit opinion should support sentiment.